Croyal, Mikaël <br/><br/>
PCSK9 inhibition with alirocumab reduces lipoprotein(a) levels in nonhuman primates by lowering apolipoprotein(a) production rate.  [electronic resource] 

 -  Clinical science (London, England : 1979)  05 2018 
 - 1075-1083 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1470-8736 
<br/><br/><label>Standard No.: </label>10.1042/CS20180040  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Antibodies, Monoclonal--pharmacology<br/>Antibodies, Monoclonal, Humanized<br/>Anticholesteremic Agents--pharmacology<br/>Apoprotein(a)--biosynthesis<br/>Cholesterol--blood<br/>Cross-Over Studies<br/>Female<br/>Lipids--blood<br/>Lipoprotein(a)--blood<br/>Macaca fascicularis<br/>Male<br/>PCSK9 Inhibitors